News

Following a forecast 0.3% decline in GDP in Q3, the UK economy is expected to contract around 0.2% each quarter from Q4 this year through to Q2 2023, resulting in GDP falling 0.3% in 2023 as a whole. This is a significant revision from the 1% growth forecast for 2023 in the EY ITEM Club’s July Summer Forecast – although the scale of the upcoming downturn is expected to be shallow relative to previous recessions thanks, in part, to the Government’s intervention on household and business energy bills.

We are excited to announce that as part of our investment programme we have introduced a high-end, ultra-fast and super-efficient slide digitalization system into our workflow. The PANNORAMIC® 1000 RX, is the flagship member of the 3DHISTECH PANNORAMIC® scanner family. It is known for its unprecedented capacity, superior image quality and flexibility. A range of scanning options are available, with brightfield scanning at resolutions of 20x, 40x, with Z stack and extended focus scanning options available too.

Despite a downturn in dealmaking, as companies seek to secure growth through innovation, M&A will need to take a central strategic role.

In brief:

- 2022 was a slow year for dealmaking in the life sciences but the final quarter saw a major uptick.

- Conditions are right for major M&A with record firepower and a wealth of targets for 2023.

- Companies will focus on the right strategic deals, which will include access to data and new technologies to secure future growth.

AMSBIO is a leading supplier of cryopreserved primary human cells for research from multiple organs including the lung, liver, intestine, and kidney. Drawing upon well-established partnerships with respected organ procurement organizations, AMSBIO has access to samples that allow direct isolation of a wide range of cells that retain their original morphological and functional characteristics.